Description
SDZ-NVI-085, also known as Naphtoxazine, is an α1 adrenergic receptor agonist potentially for the treatment of cognitive disorders and major depressive disorder. SDZ-NVI-085 behaves as a competitive antagonist of 5-hydroxytryptamine. SDZ-NVI-085 shifted 5-HT concentration-effect curves to the right, in a concentration-dependent manner, and Schild regression gave a pA2 estimate of 8.0.
Uses
SDZ NVI 085 is a compound with CNS stimulatory effects, primarily through the α1-adrenoceptor subtype, with anti-cataplexy and anti-stroke activities. SDZ NVI 085 also has a significant alertness effect and can be used to study other types of excessive sleepiness[1].
